Dienogest

Dienogest Overview

Dienogest is an orally active semisynthetic progestin belonging to the 19-nortestosterone derivative class. Chemically, it is classified as an oxosteroid featuring a cyanomethyl group at the 17alpha position and a double bond between C9 and C10 within its steroid skeleton. Despite its structural derivation from 19-nortestosterone, Dienogest lacks androgenic activity and possesses significant antiandrogenic properties.

In clinical endocrinology and gynecology, Dienogest is utilized both as a monotherapy and in combined hormonal preparations. As a standalone oral monotherapy (commonly marketed globally as Visanne at a 2 mg daily dose), it is indicated for the management of pelvic pain and inflammation associated with endometriosis. In combination with estradiol valerate or ethinylestradiol (marketed under brand names such as Natazia and Qlaira), it is indicated for oral contraception and the treatment of heavy menstrual bleeding (menorrhagia) in women without organic pathology.

What Is Dienogest and How Does It Work?

Dienogest is a small molecule steroid derivative that acts primarily as an agonist at the human progesterone receptor (PR) and an antagonist at the androgen receptor (AR).

Its core physiological and endocrine mechanisms include:

• Progesterone Receptor Agonism: Dienogest binds to target progesterone receptors, exerting intense progestagenic activity directly on endometrial tissue. Continuous administration induces initial decidualization followed by pronounced atrophy of both eutopic and ectopic endometrial tissue.
• Suppression of Estradiol & Anti-Angiogenesis: It suppresses the hypothalamic-pituitary-ovarian axis, lowering systemic serum estradiol levels to a moderately hypoestrogenic range. This deprives endometriotic lesions of trophic estrogenic stimulation, halting ectopic tissue proliferation, inflammatory cytokine cascades, and neoangiogenesis.
• Androgen Receptor Antagonism: Dienogest acts as a competitive antagonist at androgen receptors, occupying approximately 40% of the affinity of cyproterone acetate. This property helps improve androgenic symptoms such as cutaneous acne vulgaris and hirsutism.

Is Dienogest FDA Approved?

Yes, Dienogest is approved by the US FDA. It received its official New Drug Application (NDA 022284) approval on May 6, 2010, as a component of the combination drug Natazia (formulated with estradiol valerate in a four-phasic regimen) for oral contraception and the treatment of heavy menstrual bleeding (menorrhagia) without organic pathology. While standalone Dienogest (2 mg daily monotherapy, marketed globally as Visanne for endometriosis) is not approved as an independent product in the United States, it is widely approved and prescribed for endometriosis throughout Europe, Canada, Australia, Japan, and other global jurisdictions.

What Is Dienogest Used For?

• Symptomatic management of pelvic pain and reduction of endometriotic lesions in women with endometriosis (2 mg monotherapy).
• Prevention of pregnancy (oral contraception) in women electing to use hormonal birth control (combination product).
• Treatment of heavy menstrual bleeding (menorrhagia) without organic pathology in women choosing oral contraception (combination product).

Before Taking Dienogest: Contraindications & Precautions

Do not use if you have active venous thromboembolic disease, severe arterial or cardiovascular disease (myocardial infarction, stroke, ischemic heart disease), sex-steroid sensitive malignancies (e.g., breast cancer), severe liver disease, active hepatic tumors, cholestatic jaundice, or undiagnosed abnormal vaginal bleeding. Dienogest is strictly contraindicated during pregnancy and breastfeeding. Continuous monotherapy suppresses ovulation in most women but should not be relied upon as an official primary contraceptive unless taken as part of an approved combination contraceptive regimen.

Who Should Not Take Dienogest?

• Women with active venous thromboembolic disease (deep vein thrombosis, pulmonary embolism).
• Patients with present or past history of severe arterial or cardiovascular disease (myocardial infarction, cerebrovascular accident, ischemic heart disease).
• Individuals with known or suspected sex-steroid sensitive malignancies (e.g., breast cancer, endometrial carcinoma).
• Patients with severe liver disease, active hepatic adenomas/carcinomas, or cholestatic jaundice.
• Undiagnosed, abnormal vaginal bleeding.

Dienogest, Pregnancy & Fertility

Dienogest is strictly contraindicated during pregnancy. If pregnancy occurs during therapy, the drug must be discontinued immediately. Dienogest passes into human breast milk, and administration during lactation is generally not recommended due to potential effects on milk production and infant exposure. Continuous monotherapy suppresses ovulation in most women, though it should not be relied upon as an official primary contraceptive unless taken as part of an approved combination contraceptive regimen.

Tell Your Doctor Before Taking Dienogest

Inform your gynecologist or physician if you have a history of major depression, diabetes mellitus, severe hypertriglyceridemic states, cholelithiasis, or hypertension. Disclose all concurrent prescription medications, particularly Cytochrome P450 CYP3A4 inducers or inhibitors.

Dienogest Dosage & Administration

For endometriosis (Visanne 2 mg monotherapy, where approved globally), take 1 tablet orally once daily at the same time every day without interruption, starting on any day of the menstrual cycle. For oral contraception and heavy menstrual bleeding (Natazia), follow the strict 28-day four-phasic blister pack sequence containing varying ratios of dienogest and estradiol valerate. Tablets may be taken with or without food and should be swallowed whole with water.

Standard Dienogest Dosing

• Endometriosis (Visanne Monotherapy): 2 mg taken orally once daily at the same time every day, without interruption (taken continuously regardless of menstrual bleeding).
• Contraception / Menorrhagia (Natazia Combined Kit): Administered according to a strict 28-day four-phasic blister pack sequence containing varying ratios of dienogest and estradiol valerate.

How Dienogest Is Administered

• Administered via the oral route with or without food.
• Swallow tablets whole with water.
• Take doses consistently at the same time each day to maintain steady serum concentrations.
• If initiating monotherapy for endometriosis, treatment can be started on any day of the menstrual cycle.

Dienogest Clinical Efficacy & Research

Pivotal clinical trials demonstrate that Dienogest 2 mg monotherapy provides superior pelvic pain relief in women with endometriosis compared to placebo, showing equivalence in efficacy to gonadotropin-releasing hormone (GnRH) agonists (such as leuprorelin) without causing severe bone mineral density loss or severe hypoestrogenic hot flashes. In contraceptive clinical trials, the four-phasic combination of dienogest and estradiol valerate demonstrated high contraceptive efficacy (Pearl Index <1.0) and produced significant, sustained reductions in mean menstrual blood loss in women suffering from heavy menstrual bleeding.

Dienogest Side Effects & Safety Profile

Common reactions include altered bleeding patterns (spotting, irregular bleeding, amenorrhea), headaches, breast tenderness, mood changes (depression, irritability), mild weight gain, acne, and nausea. Serious adverse risks include venous and arterial thromboembolism (deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke; primarily with combined regimens), hepatic adenomas/carcinomas, severe depression, and minor reductions in bone mineral density during prolonged monotherapy in young women. Standalone Dienogest carries no FDA Black Box Warning, though combination products (Natazia) carry boxed warnings regarding cigarette smoking and cardiovascular risks in women over 35.

Common Dienogest Side Effects

• Bleeding pattern alterations, including spotting, irregular uterine bleeding, amenorrhea, or prolonged menses.
• Headaches, migraine, and breast discomfort (tenderness or enlargement).
• Mood changes, including depressed mood, irritability, and nervousness.
• Mild weight gain, acne vulgaris, and nausea.

Serious Dienogest Adverse Events

• Venous & Arterial Thromboembolism: Deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction (primarily associated with combination preparations).
• Hepatic Neoplasms & Dysfunction: Rare benign or malignant liver tumors, elevated hepatic transaminases, or jaundice.
• Severe Depression: Onset or worsening of major clinical depression.
• Bone Mineral Density Loss: Slight reduction in bone mineral density during prolonged monotherapy in adolescents and young women.

Managing Dienogest Side Effects

Irregular spotting is common during the first few months of continuous monotherapy and usually diminishes over time. If severe mood changes, sudden visual disturbances, chest pain, or leg swelling develop, seek immediate emergency medical evaluation.

Dienogest Drug Interactions & What to Avoid

Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s Wort) accelerates Dienogest clearance, reducing contraceptive and anti-endometriotic efficacy. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) and large quantities of grapefruit juice increase circulating Dienogest levels, raising toxicity risks. Do not smoke cigarettes if taking combined estrogen-progestin preparations.

Dienogest Drug-Drug Interactions

• Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin, St. John’s Wort): Accelerate the hepatic clearance of Dienogest, significantly decreasing plasma concentrations and reducing contraceptive or anti-endometriotic efficacy.
• Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir): Inhibit Dienogest metabolism, elevating plasma concentrations and increasing the risk of adverse reactions.

Dienogest, Food & Alcohol

Avoid consuming large quantities of grapefruit juice, as it inhibits CYP3A4 enzymes and increases circulating Dienogest levels.

Dienogest: Missed Dose, Overdose & Storage

For 2 mg monotherapy, take the missed tablet as soon as remembered and take the next tablet at the regular time; do not double up. For combination contraceptive kits, follow the specific missed-tablet instructions in the product packaging and use backup non-hormonal contraception as directed. Acute toxicity from overdose is low but may cause nausea, vomiting, and withdrawal bleeding. Store tablets at controlled room temperature (15°C–30°C) in original blister packaging protected from light and moisture.

Missed Dose of Dienogest

• Endometriosis Monotherapy (2 mg): Take the missed tablet as soon as remembered, then continue taking the next tablet at the regular time the following day. Do not take a double dose to make up for a missed tablet.
• Combination Contraceptive Kits: Follow the specific missed-tablet instructions detailed in the product packaging insert, using back-up non-hormonal contraception as directed.

Dienogest Overdose & Emergency

Acute toxicity following single overdose is low. Overdose may cause nausea, vomiting, and withdrawal bleeding in females. In cases of accidental acute ingestion of multiple tablets, seek supportive medical advice.

How to Store Dienogest

Store tablets at controlled room temperature between 15°C and 30°C (59°F to 86°F). Protect from light and excessive moisture. Store in original blister packaging out of reach of children.

Dienogest Patient Management & Monitoring

Obtain a baseline gynecological examination, pelvic ultrasound, Pap smear, blood pressure reading, and pregnancy test prior to starting therapy. Regularly monitor blood pressure, bleeding patterns, mood changes, and perform annual clinical breast and pelvic examinations during treatment. In adolescent patients receiving long-term continuous monotherapy, monitor bone mineral density.

Tests Before Starting Dienogest

• Baseline gynecological examination, pelvic ultrasound, and pap smear.
• Baseline blood pressure measurement and pregnancy test.
• Assessment of liver function and lipid profile if clinically indicated.

Monitoring During Dienogest Treatment

Monitor blood pressure regularly. Evaluate bleeding patterns, mood changes, and perform annual clinical breast and pelvic examinations. In adolescents, monitor bone density during prolonged continuous monotherapy.

Dienogest Do’s and Don’ts

• Do take your tablet at the same time every day.
• Do use non-hormonal barrier contraception if taking co-medications that reduce progestin levels.
• Do not smoke cigarettes if taking combined hormonal formulations.
• Do not discontinue therapy without consulting your doctor if managing chronic endometriosis pain.

Frequently Asked Questions

References

• DrugBank Database – Dienogest Clinical and Pharmacological Profile (DB09123)
• Official FDA Prescribing Information – Natazia (Estradiol Valerate and Dienogest)

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex cardiovascular conditions, medication adjustments, or dietary changes.